glp 1 for substance use disorder GLP-1 receptor agonists are promising but unproven treatments alcohol and disorders GLP-1 and Substance Use Disorder:

Functional dissociation of apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure

however, in late 2024 and early 2025 the drug manufacturers and federal regulators finally decided it was time to start fighting back and end this Wild West era (this was never supposed to be a Wild West film anyways)

GLP-1 medications and the future of obesity treatment: efficacy, safe dosing strategies, metabolic benefits, and emerging therapies [28:45]

instead they are a precaution stemming from findings in the Saxenda (liraglutide) trials where a small number of participants reported psychiatric symptoms (though these were not significantly different from the placebo group)

For multi-dose pens, removing visible larger air bubbles helps ensure accurate dosing, though small bubbles are harmless